A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group
Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE
The New England journal of medicine · 227 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1994-11-03 · N Engl J Med · vol. 331 · número 18 · págs. 1194–1199
- Editorial
- Massachusetts Medical Society
- Citado
- 408 citas · más que el 100% de estudios similares · 16.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 28 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Renal Diseases and Glomerulopathies · Fatty Acid Research and Health · Chronic Kidney Disease and Diabetes
- Palabras clave
- fish oil, IgA nephropathy, omega-3 fatty acids, proteinuria, serum creatinine, renal function decline, end-stage renal disease, hypertension, olive oil placebo
- MeSH
- humans, kidney failure, chronic, glomerulonephritis, iga, hypertension, creatinine, fatty acids, omega-3, treatment outcome, patient compliance, adult, middle aged, female, male
5 autores
- James V. Donadío🇺🇸Mayo Clinic
- Erik J. Bergstralh
- Kenneth P. Offord
- Dorothy C. Spencer
- Keith E. Holley🇺🇸Mayo Clinic
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
The n-3 fatty acids in fish oil affect eicosanoid and cytokine production and therefore have the potential to alter renal hemodynamics and inflammation. The effects of fish oil could prevent immunologic renal injury in patients with IgA nephropathy.
Methods
In a multicenter, placebo-controlled, randomized trial we tested the efficacy of fish oil in patients with IgA nephropathy who had persistent proteinuria. The daily dose of fish oil was 12 g; the placebo was a similar dose of olive oil. Serum creatinine concentrations, elevated in 68 percent of the patients at base line, and creatinine clearance were measured for two years. The primary end point was an increase of 50 percent or more in the serum creatinine concentration at the end of the study.
Results
Fifty-five patients were assigned to receive fish oil, and 51 to receive placebo. According to Kaplan-Meier estimation, 3 patients (6 percent) in the fish-oil group and 14 (33 percent) in the placebo group had increases of 50 percent or more in their serum creatinine concentrations during treatment (P = 0.002). The annual median changes in the serum creatinine concentrations were 0.03 mg per deciliter (2.7 mumol per liter) in the fish-oil group and 0.14 mg per deciliter (12.4 mumol per liter) in the placebo group. Proteinuria was slightly reduced and hypertension was controlled to a comparable degree in both groups. The cumulative percentage of patients who died or had end-stage renal disease was 40 percent in the placebo group after four years and 10 percent in the fish-oil group (P = 0.006). No patient discontinued fish-oil treatment because of adverse effects.
Conclusions
In patients with IgA nephropathy, treatment with fish oil for two years retards the rate at which renal function is lost.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.